We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info . X close

Biosurgery Market: Growth, Size, Share, and Trends

Report Code MD 3554
Published in Jul, 2025, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Biosurgery Market by Product (Bone Graft Substitutes, Sealants (Natural (Gelatin, Collagen)), Hemostatic Agents, Soft-tissue Attachments (Synthetic, Biological)), Application (Orthopedic, Urological), End User (Hospitals, ASCs) - Global Forecast to 2030

Overview

The global biosurgery market, valued at US$14.96 billion in 2024, stood at US$15.83 billion in 2025 and is projected to advance at a resilient CAGR of 6.4% from 2025 to 2030, culminating in a forecasted valuation of US$21.59 billion by the end of the period. The growing emphasis on effective blood loss management, coupled with a rise in elective surgical procedures, is significantly boosting the demand for biosurgery products. The increasing prevalence of lifestyle-related disorders and chronic diseases, along with a rising geriatric demographic, are major factors contributing to the uptick in elective surgeries worldwide. Additionally, the prevalence of severe traumatic injuries is further propelling the demand for biosurgery products as alternatives to traditional suture and ligature methods. To capitalize on this demand, manufacturers are employing organic growth strategies, including innovative product launches, which have led to the wider availability of advanced biosurgical solutions on a global scale.

Biosurgery Market

Attractive Opportunities in the Biosurgery Market

Asia Pacific

Market growth in the Asia Pacific can be attributed to the rapid growth in the geriatric population, an increasing number of chronic diseases, and supportive reimbursement policies.

Rising need for effective blood loss management in patients, an increasing volume of surgeries, and the growing prevalence of severe trauma injuries are the key factors driving the market growth.

Increasing use of combination materials for enhancing product efficacy provides lucrative opportunities for market players.

The Asia Pacific market is projected to grow at the highest CAGR during the study period.

High price of biosurgery products and an increased cost of surgical procedures is expected to restrain the market growth to a certain extent.

Global Biosurgery Market Dynamics

DRIVER: Rising need for effective blood loss management in patients

The escalating requirement for effective blood loss management is a significant catalyst for growth in the global biosurgery market, driven by an increase in trauma incidents, intricate surgical procedures, and the limitations inherent in traditional wound closure techniques. According to the National Trauma Institute, trauma remains the predominant cause of mortality among Americans aged 1 to 46, imposing an annual financial burden of approximately USD 670 billion on the U.S. healthcare system. Hemorrhage is responsible for over 60,000 deaths in the U.S. and approximately 1.5 million deaths worldwide, highlighting the critical need for advanced hemostatic interventions. Conventional wound management methods, such as sutures and staples, have proven insufficient for effectively controlling severe hemorrhage, especially in prolonged surgical operations or in acute trauma settings. Consequently, there is an increasing reliance on biosurgery products, including hemostatic agents and surgical sealants, known for their superior capacity to manage bleeding and facilitate wound healing. Additionally, the rise in road traffic accidents has further contributed to the surgical caseload and complications associated with blood loss. For example, the National Highway Traffic Safety Administration recorded 42,514 motor vehicle fatalities in the U.S. in 2022, which has led to an uptick in trauma-related surgical procedures. This mounting surgical burden, paired with the clinical benefits provided by biosurgery products, continues to accelerate the demand for innovative and effective solutions in blood loss management within the biosurgery market.

RESTRAINT: High price of biosurgery products and rising cost of surgical procedures

The escalating prices of biosurgery products and the increasing costs associated with surgical interventions significantly hinder the expansion of the biosurgery market, especially in cost-sensitive and emerging economies. Many biosurgery products—such as hemostats, sealants, adhesives, and soft-tissue repair agents—are priced at a premium due to their intricate formulations, specialized manufacturing processes, and rigorous regulatory standards. In regions with suboptimal reimbursement frameworks, particularly in developing markets, these elevated costs make biosurgery products inaccessible to a substantial segment of the patient population. Consequently, healthcare providers frequently resort to traditional wound closure techniques, including sutures and ligatures, which are considerably more affordable. Moreover, biosurgery products typically exhibit limited shelf lives and necessitate meticulous handling, which further escalates operational and storage expenditures for healthcare facilities. These challenges diminish their cost-effectiveness and constrain their uptake in resource-limited environments. Additionally, the overall rise in surgical procedure costs—including labor, equipment, and post-operative care—exerts further financial strain on hospitals and patients, thereby diminishing the receptiveness to adopting premium-priced biosurgery solutions. This scenario underscores an urgent need for the development of cost-effective, user-friendly, and durable biosurgery alternatives to foster broader acceptance and ensure sustainable growth within global healthcare systems.

 

OPPORTUNITY: Growing adoption of advanced biosurgery products in emerging markets

The increasing uptake of advanced biosurgical products in emerging markets signals a substantial opportunity for the expansion of the biosurgery sector. Regions such as Asia Pacific, Latin America, and the Middle East & Africa—most notably China, India, Brazil, and Malaysia—are experiencing heightened demand driven by a significant patient population affected by cardiovascular, orthopedic, gynecological, and various abdominal disorders necessitating surgical intervention. Key factors such as escalating healthcare expenditures, rising health awareness, and enhanced accessibility to healthcare services are fostering a more favorable environment for the adoption of advanced surgical technologies, including biosurgery solutions. Additionally, the swift advancement of healthcare infrastructure, complemented by government initiatives aimed at fortifying national healthcare systems, is facilitating the integration of innovative surgical methodologies. Medical tourism serves as a critical growth catalyst in this landscape; countries like India and Malaysia are becoming destinations for high-quality surgical procedures offered at a fraction of the costs found in Western nations. This trend is attracting a global patient demographic, thereby increasing procedural volumes. As the cost parity between traditional wound closure methods and biosurgical alternatives diminishes, and with local companies and distributors broadening their market presence, biosurgery manufacturers are strategically positioned to exploit these emerging opportunities. This can be achieved through the establishment of strategic partnerships, the development of localized product offerings, and investment in capacity building within these high-potential markets.

CHALLENGES: Stringent regulatory framework

The stringent regulatory landscape presents a significant barrier to the advancement of the biosurgery market. The process of developing and commercializing new biosurgical products necessitates substantial investments in research and development, lengthy development timelines, and the navigation of complex regulatory pathways. In prominent markets such as the United States, the FDA requires Premarket Approval (PMA) for biosurgical products, especially for high-risk Class III devices like hemostats and sealants. This entails that manufacturers must provide exhaustive clinical trial data demonstrating both safety and efficacy. The clinical evaluation process often extends over 7 to 8 years and is accompanied by significant costs and a low probability of success. Products in the biosurgery category, including adhesion barriers and semi-synthetic sealants, encounter additional challenges due to a scarcity of clinically significant trial outcomes, which further diminishes their chances for regulatory approval. These rigorous requirements not only extend time-to-market but also deter smaller firms and new entrants from innovating within this sector. Even established companies must meticulously assess the risk-reward balance prior to committing resources to new biosurgical solutions. Consequently, the regulatory burden stifles product innovation and impedes market growth, representing a critical limitation on the long-term development and competitiveness of the biosurgery industry.

Global Biosurgery Market Ecosystem Analysis

The biosurgery market is a complex ecosystem made up of various interconnected stakeholders involved throughout the product lifecycle, from research and development to end use. The market is categorized into several product types, including hemostatic agents, bone-graft substitutes, soft tissue attachments, adhesion barriers, surgical sealants, and other related biosurgical products. At the heart of this ecosystem are manufacturers who handle end-to-end processes, including in-house research and development, product formulation, testing, optimization, regulatory compliance, and the final product launch. These manufacturers often collaborate with Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs) to improve development efficiency and reduce the time it takes to bring products to market. Biosurgery products are distributed through a mix of third-party distributors and e-commerce platforms, ensuring broad market coverage and product availability across different regions. The end users, including hospitals, ambulatory surgical centers, and specialty clinics, play a crucial role as they employ biosurgery products in a wide range of surgical procedures and wound management. This ecosystem is supported by regulatory bodies, academic research institutions, and strategic partnerships that drive innovation, ensure quality compliance, and support market growth. Overall, the biosurgery ecosystem is dynamic and heavily relies on collaboration across various functional areas to deliver clinically effective and commercially viable products.

Biosurgery Market
 

By product, the bone-graft substitute segment held the highest market share in 2024.

On the basis of products, the biosurgery market is segmented into bone graft substitutes, soft-tissue attachments, hemostatic agents, surgical sealants & adhesives, adhesion barriers, and staple-line reinforcement agents. The bone-graft substitute segment constitutes the leading market share within the biosurgery sector, driven by its expanding utilization in orthopedic and dental applications and its significant clinical and logistical benefits over traditional autografts. These substitutes mitigate the necessity for harvesting autologous bone, thus diminishing surgical duration, patient morbidity, and the risk of post-operative complications associated with autologous grafting. Bone-graft substitutes encompass a range of materials, including demineralized bone matrix (DBM), synthetic ceramics, and allografts, presented in various formats, such as pellets, putty, paste, strips, gels, and blocks. This versatility allows for tailored applications in accordance with specific surgical needs. Moreover, the standardization and abundance of these substitutes effectively address the limitations associated with autograft supply, particularly in scenarios involving extensive or intricate bone defects. Advancements in biomaterials technology have further augmented the osteoconductive and osteoinductive properties of these substitutes, thereby enhancing their efficacy in facilitating bone healing and regeneration. The rising incidence of orthopedic disorders, trauma, and spinal pathologies worldwide, along with the increased demand for dental reconstructive interventions, continues to propel the market for these products. Collectively, these dynamics consolidate the position of bone-graft substitutes as the preferred option among surgeons and healthcare providers, solidifying their predominance in the biosurgery landscape.

By end user, the hospitals segment held the largest market share in 2024.

On the basis of end users, the biosurgery market is bifurcated into ambulatory surgical centers, hospitals, clinics, and other end users. In 2024, the hospitals segment dominated the biosurgery market, largely attributable to the substantial volume of complex and minimally invasive surgical procedures performed within these institutions. Hospitals are equipped with advanced technological infrastructure, experienced surgical teams, and comprehensive post-operative care, positioning them as the preferred environments for critical interventions that necessitate biosurgical products, including hemostats, sealants, adhesion barriers, and bone-graft substitutes. The escalating incidence of chronic conditions, trauma cases, orthopedic disorders, and cardiovascular diseases has correspondingly increased surgical volumes, particularly in public and multi-specialty hospitals. This heightened patient influx propels the demand for biosurgery solutions. Additionally, hospitals typically benefit from favorable reimbursement frameworks and establish long-term supplier relationships, enhancing procurement efficiency and ensuring a steady supply of biosurgical products. Collectively, these factors underscore the preeminent role of the hospital segment in the global biosurgery landscape.

By region, the Asia Pacific is expected to showcase the highest CAGR during the forecast period.

On the basis of region, the Biosurgery market is bifurcated into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. During the forecast period, the Asia Pacific region is poised to emerge as the fastest-growing market for insulin delivery devices, driven by several key factors. The region's rapidly advancing healthcare infrastructure, combined with a surge in surgical procedure volumes and an increasing embrace of cutting-edge surgical technologies, is significantly impacting market dynamics. Countries such as China, India, and Japan are experiencing notable upticks in both inpatient surgeries and cosmetic procedures. For instance, data from Statista indicates that Chinese hospitals performed over 82.7 million inpatient surgical operations in 2023, while Japan documented approximately 302.5 thousand cosmetic procedures focused on the face and head in 2022. This escalating surgical burden is subsequently fueling demand for biosurgery products, including hemostats, sealants, and bone-graft substitutes. Moreover, rising healthcare expenditures, heightened awareness around advanced treatment modalities, and robust government initiatives aimed at healthcare modernization are further propelling market expansion. The significant influx of medical tourism, particularly in India, Thailand, and Malaysia, is also encouraging the adoption of high-quality biosurgery products. Collectively, these factors contribute to making the Asia Pacific the most dynamic regional market for insulin delivery devices.

CHINA: LARGEST MARKET SHARE IN ASIA PACIFIC IN 2024
ASIA PACIFIC: FASTEST-GROWING MARKET IN REGION
Biosurgery Market

Recent Developments of Biosurgery Market

  • Agreement: In January 2025, Kuros Biosciences USA, Inc. entered into an exclusive strategic agreement with Medtronic’s Spinal Division, appointing Medtronic as the exclusive sales agent for MagnetOs in designated territories for spinal surgery applications.
  • Product Approval: In January 2024, Kuros Biosciences received US FDA 510(k) clearance for the use of MagnetOs Granules in interbody spinal procedures and regulatory approval for MagnetOs Granules and MagnetOs Putty in New Zealand.
  • Product Approval: In November 2023, Kuros Biosciences announced that MagnetOs Flex Matrix had been cleared for use in the interbody space by the US Food and Drug Administration (FDA).
  • Agreement: In January 2023, Zimmer Biomet Holdings, Inc. announced that it had entered into a definitive agreement to acquire Embody, Inc., a company specializing in soft tissue healing, for USD 155 million at closing. Up to USD 120 million is contingent upon the achievement of future regulatory and commercial milestones over a three-year period.
  • Product Launch: In October 2022, Orthofix Medical Inc. announced the full market release and first implants of Legacy Demineralized Bone Matrix (DBM), a putty for filling voids or gaps in boney defects or traumatic injuries of the spine, pelvis, or extremities.
  • Agreement: In October 2022, Orthofix Medical, Inc. and SeaSpine, Inc. announced they had entered into a definitive agreement to combine an all-stock merger of equals. The merger was completed in January 2023.

Key Market Players

Want to explore hidden markets that can drive new revenue in Biosurgery Market?

Scope of the Report

Report Metric Details
Market size available for years 2022-2030
Base Year Considered 2024
Forecast period 2025-2030
Forecast units Value (USD Million/Billion)
Segments covered Product, Application, End User, Region
Geographies covered North America (US and Canada), Europe (Germany, UK, France, Italy, Spain, and Rest of Europe), Asia Pacific (Japan, China, Australia, South Korea, India, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

Frequently Asked Questions (FAQ)

Which are the top industry players in the global biosurgery market?

Key players include Johnson & Johnson Services, Inc. (US), Baxter (US), Medtronic (Ireland), Becton, Dickinson and Company (BD) (US), B. Braun SE (Germany), and Stryker (US).

What are some of the major drivers for this market?

The increasing volume of surgeries and prevalence of severe trauma injuries are driving R&D efforts, resulting in the launch of technologically advanced products that support market growth.

Which end users have been included in the global biosurgery market?

Hospitals, Clinics, Ambulatory Surgical Centers, and Other End Users.

Which type of biosurgery products held the largest market share in 2024?

The bone graft substitute segment held the largest market share in 2024.

Which region is lucrative for the biosurgery market?

The Asia Pacific region is projected to experience the highest CAGR during the forecast period.

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Biosurgery Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
36
RESEARCH METHODOLOGY
42
EXECUTIVE SUMMARY
55
PREMIUM INSIGHTS
59
MARKET OVERVIEW
63
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Increasing volume of surgeries and growing prevalence of severe trauma injuries
    - Rising need for effective blood loss management
    RESTRAINTS
    - High price of biosurgery products and surgical procedures
    OPPORTUNITIES
    - Rising use of combination materials for enhancing product efficacy
    - Growing adoption of adhesive dentistry procedures
    CHALLENGES
    - Stringent regulatory framework
    - Scarcity of skilled personnel for effective use of biosurgery products
  • 5.3 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Hemostatic & sealant biomaterial technology
    - Tissue engineering & regenerative medicine technology
    COMPLEMENTARY TECHNOLOGIES
    - Surgical imaging & navigation technology
    - Sterilization & preservation technology
    ADJACENT TECHNOLOGIES
    - 3D printing technology
    - Minimally invasive technology
  • 5.4 INDUSTRY TRENDS
    GROWING PREFERENCE FOR GELATIN-BASED ADHESIVES & HYDROGELS IN SURGICAL PROCEDURES
    USE OF NANOTECHNOLOGY FOR DEVELOPING NEXT-GENERATION ADHESIVES
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 ECOSYSTEM ANALYSIS
  • 5.7 SUPPLY CHAIN ANALYSIS
  • 5.8 TRADE ANALYSIS
    IMPORT DATA FOR HS CODE 300610, 2019–2024
    EXPORT DATA FOR HS CODE 300610, 2019–2024
  • 5.9 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF BUYERS
    BARGAINING POWER OF SUPPLIERS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.10 KEY STAKEHOLDERS & BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    KEY BUYING CRITERIA
  • 5.11 REGULATORY ANALYSIS
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    REGULATORY ANALYSIS
    - North America
    - Europe
    - Asia Pacific
    - Latin America
    - Middle East & Africa
  • 5.12 PATENT ANALYSIS
    INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.13 PRICING ANALYSIS
    AVERAGE SELLING PRICE TREND OF BIOSURGERY PRODUCTS, BY KEY PLAYER, 2022–2024
    AVERAGE SELLING PRICE TREND OF BIOSURGERY PRODUCTS, BY REGION, 2022–2024
  • 5.14 KEY CONFERENCES & EVENTS, 2025–2026
  • 5.15 ADJACENT MARKET ANALYSIS
    ADHESION BARRIERS MARKET
  • 5.16 UNMET NEEDS/END-USER EXPECTATIONS
  • 5.17 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
  • 5.18 INVESTMENT & FUNDING SCENARIO
  • 5.19 IMPACT OF AI/GEN AI ON BIOSURGERY MARKET
  • 5.20 IMPACT OF 2025 US TARIFF ON BIOSURGERY MARKET
    INTRODUCTION
    KEY TARIFF RATES
    PRICE IMPACT ANALYSIS
    IMPACT ON COUNTRIES/REGIONS
    - North America
    - Europe
    - Asia Pacific
    IMPACT ON END-USE INDUSTRIES
BIOSURGERY MARKET, BY PRODUCT
95
  • 6.1 INTRODUCTION
  • 6.2 BONE-GRAFT SUBSTITUTES
    DEMINERALIZED BONE MATRIX
    - Rising volume of spinal fusion, joint reconstruction, and replacement surgeries to drive segment
    SYNTHETIC BONE GRAFTS
    - High compressive strength, osteoconductive properties, and minimal risk of disease transmission to fuel segment growth
    BONE MORPHOGENETIC PROTEINS
    - Increasing prevalence of spinal deformities, disc degeneration, trauma, and sport-related injuries to propel segment growth
    OTHER BONE-GRAFT SUBSTITUTES
  • 6.3 SURGICAL SEALANTS & ADHESIVES
    NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES
    - Natural/Biological surgical sealants & adhesives, by type
    - Natural/biological surgical sealants & adhesives, by origin
    SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES
    - PEG hydrogel-based sealants & adhesives
    - Cyanoacrylate-based sealants & adhesives
    - Urethane-based sealants & adhesives
    - Other synthetic & semi-synthetic surgical sealants & adhesives
  • 6.4 ADHESION BARRIERS
    SYNTHETIC ADHESION BARRIERS
    - Hyaluronic acid-based adhesion barriers
    - Regenerated cellulose-based adhesion barriers
    - PEG-based adhesion barriers
    - Other synthetic adhesion barriers
    NATURAL ADHESION BARRIERS
    - Collagen & protein adhesion barriers
    - Fibrin-based adhesion barriers
  • 6.5 STAPLE-LINE REINFORCEMENT AGENTS
    RISING VOLUME OF COMPLEX SURGICAL PROCEDURRES TO DRIVE MARKET
  • 6.6 SOFT-TISSUE ATTACHMENTS
    SYNTHETIC MESHES
    - Increasing demand for safe and cost-effective soft tissue reinforcement to drive segment
    BIOLOGICAL MESHES
    - Allografts
    - Xenografts
  • 6.7 HEMOSTATIC AGENTS
    THROMBIN-BASED HEMOSTATIC AGENTS
    - Rising demand for safer and fast-acting clotting agents to drive growth of thrombin-based hemostats
    OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATIC AGENTS
    - Rising adoption of plant-based and absorbable hemostats to propel segment growth
    COMBINATION HEMOSTATIC AGENTS
    - Superior efficacy in complex bleeding control to drive adoption of combination hemostatic agents globally
BIOSURGERY MARKET, BY APPLICATION
157
  • 7.1 INTRODUCTION
  • 7.2 ORTHOPEDIC SURGERY
    INCREASING INCIDENCE OF SPORTS INJURIES AND GROWING PREVALENCE OF OSTEOPOROSIS TO PROPEL MARKET GROWTH
  • 7.3 GENERAL SURGERY
    HIGH GERIATRIC POPULATION AND INCREASED PREVALENCE OF OBESITY TO FUEL DEMAND FOR BARIATRIC INTERVENTIONS
  • 7.4 NEUROLOGICAL SURGERY
    GROWING PREVALENCE OF NEUROLOGICAL DISORDERS TO AUGMENT MARKET GROWTH
  • 7.5 CARDIOVASCULAR SURGERY
    BIOSURGERY PRODUCTS TO REPLACE CONVENTIONAL SUTURE-BASED METHODS IN CARDIOVASCULAR PROCEDURES
  • 7.6 RECONSTRUCTIVE SURGERY
    INCREASING FACIAL COSMETIC SURGERIES AND BREAST RECONSTRUCTION PROCEDURES TO PROPEL MARKET GROWTH
  • 7.7 GYNECOLOGICAL SURGERY
    COMPLEXITY OF GYNECOLOGICAL PROCEDURES TO FUEL DEMAND FOR ADVANCED BIOSURGICAL PRODUCTS
  • 7.8 UROLOGICAL SURGERY
    USE OF BIOSURGERY PRODUCTS IN COMPLEX RECONSTRUCTIVE UROLOGICAL SURGERIES TO STIMULATE SEGMENT GROWTH
  • 7.9 THORACIC SURGERY
    RISING INCIDENCE OF PULMONARY CHRONIC DISEASES TO SPUR MARKET GROWTH
  • 7.10 OTHER APPLICATIONS
BIOSURGERY MARKET, BY END USER
173
  • 8.1 INTRODUCTION
  • 8.2 HOSPITALS
    RISING NUMBER OF REIMBURSED INPATIENT PROCEDURES TO DRIVE POPULARITY OF HOSPITALS FOR SURGERIES
  • 8.3 CLINICS
    QUICKER CONSULTATION SERVICES AND MINIMAL PATIENT STAYS TO FAVOR MARKET GROWTH
  • 8.4 AMBULATORY SURGICAL CENTERS
    RISING DEMAND FOR COST-EFFECTIVE SAME-DAY SURGERIES TO AUGMENT MARKET GROWTH
  • 8.5 OTHER END USERS
BIOSURGERY MARKET, BY REGION
180
  • 9.1 INTRODUCTION
  • 9.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    - US to dominate North American biosurgery market during forecast period
    CANADA
    - Growing prevalence of chronic diseases to drive market
  • 9.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    - Robust healthcare investments and improved infrastructure to support adoption of advanced surgical technologies
    UK
    - Rise in popularity of cosmetic and reconstructive surgeries to fuel market growth
    FRANCE
    - Presence of well-established healthcare system and high geriatric population to boost market growth
    ITALY
    - Increasing surgical volume to fuel market growth
    SPAIN
    - Rising surgical demand to boost need for biosurgery products
    REST OF EUROPE
  • 9.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    CHINA
    - Increasing number of domestic biosurgery and medical device manufacturers to aid market growth
    INDIA
    - Rising healthcare awareness and favorable government support to stimulate market growth
    JAPAN
    - Advanced healthcare system and high geriatric population to spur market growth
    SOUTH KOREA
    - Rising number of cosmetic surgeries and growing adoption of innovative medical technologies to drive market
    AUSTRALIA
    - Well-established healthcare system and high government medical expenditure to favor market growth
    REST OF ASIA PACIFIC
  • 9.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Rapidly aging population and high prevalence of chronic diseases to support market growth
    MEXICO
    - Enhanced focus on medical tourism to drive market
    REST OF LATIN AMERICA
  • 9.6 MIDDLE EAST & AFRICA
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    GCC COUNTRIES
    - Rising prevalence of chronic diseases to drive market
    REST OF MIDDLE EAST & AFRICA
COMPETITIVE LANDSCAPE
332
  • 10.1 INTRODUCTION
  • 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOSURGERY MARKET
  • 10.3 REVENUE ANALYSIS, 2020–2024
  • 10.4 MARKET SHARE ANALYSIS, 2024
  • 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2024
    - Company footprint
    - Region footprint
    - Product footprint
    - Application footprint
    - End-user footprint
  • 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    - Detailed list of key startups/SMEs
    - Competitive benchmarking of key startups/SMEs
  • 10.7 COMPANY VALUATION & FINANCIAL METRICS
    FINANCIAL METRICS
    COMPANY VALUATION
  • 10.8 BRAND/PRODUCT COMPARISON
  • 10.9 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES & APPROVALS
    DEALS
COMPANY PROFILES
350
  • 11.1 KEY PLAYERS
    BAXTER
    - Business overview
    - Products offered
    - MnM view
    B. BRAUN SE
    - Business overview
    - Products offered
    - MnM view
    BECTON, DICKINSON AND COMPANY (BD)
    - Business overview
    - Products offered
    - MnM view
    JOHNSON & JOHNSON
    - Business overview
    - Products offered
    - MnM view
    MEDTRONIC
    - Business overview
    - Products offered
    - MnM view
    INTEGRA LIFESCIENCES CORPORATION
    - Business overview
    - Products offered
    COMMONWEALTH SERUM LABORATORIES LIMITED (CSL)
    - Business overview
    - Products offered
    HEMOSTASIS, LLC
    - Business overview
    - Products offered
    PFIZER INC.
    - Business overview
    - Products offered
    STRYKER
    - Business overview
    - Products offered
    ARTIVION, INC.
    - Business overview
    - Products offered
    ZIMMER BIOMET
    - Business overview
    - Products offered
    - Recent developments
    KUROS BIOSCIENCES
    - Business overview
    - Products offered
    - Recent developments
    ORTHOFIX MEDICAL INC.
    - Business overview
    - Products offered
    - Recent developments
    SMITH & NEPHEW
    - Business overview
    - Products offered
  • 11.2 OTHER PLAYERS
    TISSUE REGENIX
    BETATECH MEDICAL
    MERIL LIFE SCIENCES PVT. LTD.
    GLOBUS MEDICAL
    SAMYANG HOLDINGS CORPORATION
    AROA BIOSURGERY LIMITED
    MEYER-HAAKE GMBH
    ADVANCED MEDICAL SOLUTIONS GROUP PLC
    BIOCER ENTWICKLUNGS-GMBH
    WILTROM
APPENDIX
404
  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 12.3 CUSTOMIZATION OPTIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 BIOSURGERY MARKET: INCLUSIONS & EXCLUSIONS
  • TABLE 2 STANDARD CURRENCY CONVERSION RATES
  • TABLE 3 BIOSURGERY MARKET: STUDY ASSUMPTIONS
  • TABLE 4 BIOSURGERY MARKET: RISK ANALYSIS
  • TABLE 5 IMPORT DATA FOR HS CODE 300610, BY COUNTRY, 2019–2024 (USD THOUSAND)
  • TABLE 6 EXPORT DATA FOR HS CODE 300610, BY COUNTRY, 2019–2024 (USD THOUSAND)
  • TABLE 7 BIOSURGERY MARKET: PORTER’S FIVE FORCES
  • TABLE 8 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE BIOSURGERY PRODUCTS
  • TABLE 9 KEY BUYING CRITERIA FOR BIOSURGERY PRODUCTS
  • TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 AVERAGE SELLING PRICE TREND OF BIOSURGERY PRODUCTS, BY KEY PLAYER, 2022–2024 (USD)
  • TABLE 16 AVERAGE SELLING PRICE TREND OF BIOSURGERY PRODUCTS, BY REGION, 2022–2024 (USD)
  • TABLE 17 BIOSURGERY MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026
  • TABLE 18 BIOSURGERY MARKET: UNMET NEEDS/END-USER EXPECTATIONS
  • TABLE 19 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 20 KEY PRODUCT-RELATED TARIFF EFFECTIVE FOR BIOSURGERY PRODUCTS
  • TABLE 21 BIOSURGERY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 22 BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 23 BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 24 MAJOR DEMINERALIZED BONE MATRIX PRODUCTS AVAILABLE IN MARKET
  • TABLE 25 DEMINERALIZED BONE MATRIX MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 26 MAJOR SYNTHETIC BONE GRAFTS AVAILABLE IN MARKET
  • TABLE 27 SYNTHETIC BONE GRAFTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 28 MAJOR BONE MORPHOGENETIC PROTEINS AVAILABLE IN MARKET
  • TABLE 29 BONE MORPHOGENETIC PROTEINS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 30 OTHER BONE-GRAFT SUBSTITUTES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 31 BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 32 BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 33 NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 34 NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 35 MAJOR FIBRIN-BASED SEALANTS & ADHESIVES AVAILABLE IN MARKET
  • TABLE 36 FIBRIN-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 37 MAJOR COLLAGEN BASED-SEALANTS & ADHESIVES AVAILABLE IN MARKET
  • TABLE 38 COLLEGEN-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 39 MAJOR GELATIN BASED-SEALANTS & ADHESIVES AVAILABLE IN MARKET
  • TABLE 40 GELATIN-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 41 MAJOR ALBUMIN BASED-SEALANTS & ADHESIVES AVAILABLE IN MARKET
  • TABLE 42 ALBUMIN-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 43 OTHER NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 44 NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)
  • TABLE 45 ANIMAL-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 46 HUMAN BLOOD-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 47 SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 48 SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 49 MAJOR PRODUCTS PEG HYDROGEL-BASED SEALANTS & ADHESIVES AVAILABLE IN MARKET
  • TABLE 50 PEG HYROGEL-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 51 MAJOR CYANOACRYLATE-BASED SEALANTS & ADHESIVES AVAILABLE IN MARKET
  • TABLE 52 CYANOACRYLATE-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 53 URETHANE-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 54 OTHER SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 55 BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 56 BIOSURGERY MARKET FOR ADHESION BARRIERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 57 SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 58 SYNTHETIC ADHESION BARRIERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 59 MAJOR HYALURONIC ACID-BASED ADHESION BARRIERS AVAILABLE IN MARKET
  • TABLE 60 HYALURONIC ACID-BASED ADHESION BARRIERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 61 MAJOR REGENERATED CELLULOSE-BASED ADHESION BARRIERS AVAILABLE IN MARKET
  • TABLE 62 REGENERATED CELLULOSE -BASED ADHESION BARRIERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 63 MAJOR PEG-BASED ADHESION BARRIERS AVAILABLE IN MARKET
  • TABLE 64 PEG-BASED ADHESION BARRIERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 65 OTHER SYNTHETIC ADHESION BARRIERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 66 NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 67 MAJOR COLLAGEN & PROTEIN ADHESION BARRIERS AVAILABLE IN MARKET
  • TABLE 68 COLLAGEN & PROTEIN ADHESION BARRIERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 69 MAJOR FIBRIN-BASED ADHESION BARRIERS AVAILABLE IN MARKET
  • TABLE 70 FIBRIN-BASED ADHESION BARRIERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 71 MAJOR STAPLE-LINE REINFORCEMENT AGENTS AVAILABLE IN MARKET
  • TABLE 72 BIOSURGERY MARKET FOR STAPLE-LINE REINFORCEMENT AGENTS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 73 BIOSURGERY MARKET FOR SOFT-TISSUE ATTCHMENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 74 BIOSURGERY MARKET FOR SOFT-TISSUE ATTCHMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 75 MAJOR SYNTHETIC MESHES AVAILABLE IN MARKET
  • TABLE 76 SYNTHETIC MESHES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 77 MAJOR BIOLOGICAL MESHES AVAILABLE IN MARKET
  • TABLE 78 BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 79 BIOLOGICAL MESHES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 80 ALLOGRAFTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 81 XENOGRAFTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 82 MAJOR HEMOSTATIC AGENTS AVAILABLE IN MARKET
  • TABLE 83 BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 84 BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 85 MAJOR THROMBIN-BASED HEMOSTATIC AGENTS AVAILABLE IN MARKET
  • TABLE 86 THROMBIN-BASED HEMOSTATIC AGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 87 MAJOR OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATIC AGENTS AVAILABLE IN MARKET
  • TABLE 88 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATIC AGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 89 MAJOR COMBINATION HEMOSTATIC AGENTS AVAILABLE IN MARKET
  • TABLE 90 COMBINATION HEMOSTATIC AGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 91 BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 92 BIOSURGERY MARKET FOR ORTHOPEDIC SURGERY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 93 BIOSURGERY MARKET FOR GENERAL SURGERY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 94 BIOSURGERY MARKET FOR NEUROLOGICAL SURGERY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 95 BIOSURGERY MARKET FOR CARDIOVASCULAR SURGERY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 96 BIOSURGERY MARKET FOR RECONSTRUCTIVE SURGERY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 97 BIOSURGERY MARKET FOR GYNECOLOGICAL SURGERY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 98 BIOSURGERY MARKET FOR UROLOGICAL SURGERY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 99 BIOSURGERY MARKET FOR THORACIC SURGERY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 100 BIOSURGERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 101 BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 102 BIOSURGERY MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 103 BIOSURGERY MARKET FOR CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 104 BIOSURGERY MARKET FOR AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 105 BIOSURGERY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 106 BIOSURGERY MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 107 NORTH AMERICA: BIOSURGERY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 108 NORTH AMERICA: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 109 NORTH AMERICA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 110 NORTH AMERICA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 111 NORTH AMERICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 112 NORTH AMERICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)
  • TABLE 113 NORTH AMERICA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 114 NORTH AMERICA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 115 NORTH AMERICA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 116 NORTH AMERICA: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 117 NORTH AMERICA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS,BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 118 NORTH AMERICA: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 119 NORTH AMERICA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 120 NORTH AMERICA: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 121 NORTH AMERICA: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 122 US: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 123 US: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 124 US: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 125 US: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 126 US: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)
  • TABLE 127 US: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 128 US: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 129 US: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 130 US: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 131 US: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 132 US: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 133 US: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 134 US: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 135 US: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 136 CANADA: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 137 CANADA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 138 CANADA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 139 CANADA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 140 CANADA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)
  • TABLE 141 CANADA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 142 CANADA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 143 CANADA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 144 CANADA: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 145 CANADA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 146 CANADA: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 147 CANADA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 148 CANADA: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 149 CANADA: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 150 EUROPE: BIOSURGERY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 151 EUROPE: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 152 EUROPE: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 153 EUROPE: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 154 EUROPE: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 155 EUROPE: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)
  • TABLE 156 EUROPE: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 157 EUROPE: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 158 EUROPE: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 159 EUROPE: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 160 EUROPE: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 161 EUROPE: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 162 EUROPE: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 163 EUROPE: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 164 EUROPE: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 165 GERMANY: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 166 GERMANY: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 167 GERMANY: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 168 GERMANY: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 169 GERMANY: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)
  • TABLE 170 GERMANY: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 171 GERMANY: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 172 GERMANY: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 173 GERMANY: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 174 GERMANY: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 175 GERMANY: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 176 GERMANY: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 177 GERMANY: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 178 GERMANY: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 179 UK: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 180 UK: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 181 UK: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 182 UK: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 183 UK: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)
  • TABLE 184 UK: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 185 UK: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 186 UK: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 187 UK: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 188 UK: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 189 UK: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 190 UK: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 191 UK: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 192 UK: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 193 FRANCE: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 194 FRANCE: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 195 FRANCE: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 196 FRANCE: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 197 FRANCE: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)
  • TABLE 198 FRANCE: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 199 FRANCE: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 200 FRANCE: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 201 FRANCE: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 202 FRANCE: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 203 FRANCE: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 204 FRANCE: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 205 FRANCE: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 206 FRANCE: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 207 ITALY: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 208 ITALY: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 209 ITALY: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 210 ITALY: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 211 ITALY: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)
  • TABLE 212 ITALY: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 213 ITALY: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 214 ITALY: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 215 ITALY: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 216 ITALY: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 217 ITALY: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 218 ITALY: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 219 ITALY: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 220 ITALY: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 221 SPAIN: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 222 SPAIN: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 223 SPAIN: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 224 SPAIN: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 225 SPAIN: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)
  • TABLE 226 SPAIN: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 227 SPAIN: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 228 SPAIN: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 229 SPAIN: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 230 SPAIN: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 231 SPAIN: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 232 SPAIN: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 233 SPAIN: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 234 SPAIN: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 235 REST OF EUROPE: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 236 REST OF EUROPE: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 237 REST OF EUROPE: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 238 REST OF EUROPE: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 239 REST OF EUROPE: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)
  • TABLE 240 REST OF EUROPE: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 241 REST OF EUROPE: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 242 REST OF EUROPE: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 243 REST OF EUROPE: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 244 REST OF EUROPE: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 245 REST OF EUROPE: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 246 REST OF EUROPE: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 247 REST OF EUROPE: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 248 REST OF EUROPE: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 249 ASIA PACIFIC: BIOSURGERY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 250 ASIA PACIFIC: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 251 ASIA PACIFIC: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 252 ASIA PACIFIC: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 253 ASIA PACIFIC: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 254 ASIA PACIFIC: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)
  • TABLE 255 ASIA PACIFIC: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 256 ASIA PACIFIC: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 257 ASIA PACIFIC: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 258 ASIA PACIFIC: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 259 ASIA PACIFIC: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 260 ASIA PACIFIC: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 261 ASIA PACIFIC: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 262 ASIA PACIFIC: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 263 ASIA PACIFIC: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 264 CHINA: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 265 CHINA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 266 CHINA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 267 CHINA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 268 CHINA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)
  • TABLE 269 CHINA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 270 CHINA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 271 CHINA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 272 CHINA: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 273 CHINA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 274 CHINA: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 275 CHINA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 276 CHINA: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 277 CHINA: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 278 INDIA: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 279 INDIA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 280 INDIA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 281 INDIA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 282 INDIA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)
  • TABLE 283 INDIA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 284 INDIA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 285 INDIA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 286 INDIA: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 287 INDIA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 288 INDIA: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 289 INDIA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 290 INDIA: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 291 INDIA: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 292 JAPAN: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 293 JAPAN: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 294 JAPAN: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 295 JAPAN: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 296 JAPAN: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)
  • TABLE 297 JAPAN: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 298 JAPAN: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 299 JAPAN: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 300 JAPAN: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 301 JAPAN: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 302 JAPAN: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 303 JAPAN: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 304 JAPAN: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 305 JAPAN: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 306 SOUTH KOREA: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 307 SOUTH KOREA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 308 SOUTH KOREA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 309 SOUTH KOREA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 310 SOUTH KOREA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)
  • TABLE 311 SOUTH KOREA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 312 SOUTH KOREA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 313 SOUTH KOREA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 314 SOUTH KOREA: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 315 SOUTH KOREA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 316 SOUTH KOREA: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 317 SOUTH KOREA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 318 SOUTH KOREA: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 319 SOUTH KOREA: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 320 AUSTRALIA: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 321 AUSTRALIA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 322 AUSTRALIA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 323 AUSTRALIA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 324 AUSTRALIA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)
  • TABLE 325 AUSTRALIA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 326 AUSTRALIA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 327 AUSTRALIA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 328 AUSTRALIA: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 329 AUSTRALIA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 330 AUSTRALIA: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 331 AUSTRALIA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 332 AUSTRALIA: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 333 AUSTRALIA: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 334 REST OF ASIA PACIFIC: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 335 REST OF ASIA PACIFIC: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 336 REST OF ASIA PACIFIC: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 337 REST OF ASIA PACIFIC: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 338 REST OF ASIA PACIFIC: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)
  • TABLE 339 REST OF ASIA PACIFIC: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 340 REST OF ASIA PACIFIC: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 341 REST OF ASIA PACIFIC: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 342 REST OF ASIA PACIFIC: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 343 REST OF ASIA PACIFIC: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 344 REST OF ASIA PACIFIC: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 345 REST OF ASIA PACIFIC: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 346 REST OF ASIA PACIFIC: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 347 REST OF ASIA PACIFIC: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 348 LATIN AMERICA: BIOSURGERY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 349 LATIN AMERICA: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 350 LATIN AMERICA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 351 LATIN AMERICA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 352 LATIN AMERICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 353 LATIN AMERICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)
  • TABLE 354 LATIN AMERICA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 355 LATIN AMERICA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 356 LATIN AMERICA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 357 LATIN AMERICA: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 358 LATIN AMERICA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 359 LATIN AMERICA: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 360 LATIN AMERICA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 361 LATIN AMERICA: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 362 LATIN AMERICA: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 363 BRAZIL: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 364 BRAZIL: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 365 BRAZIL: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 366 BRAZIL: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 367 BRAZIL: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)
  • TABLE 368 BRAZIL: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 369 BRAZIL: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 370 BRAZIL: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 371 BRAZIL: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 372 BRAZIL: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE,2023–2030 (USD MILLION)
  • TABLE 373 BRAZIL: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 374 BRAZIL: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 375 BRAZIL: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 376 BRAZIL: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 377 MEXICO: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 378 MEXICO: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 379 MEXICO: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 380 MEXICO: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 381 MEXICO: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)
  • TABLE 382 MEXICO: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 383 MEXICO: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 384 MEXICO: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 385 MEXICO: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 386 MEXICO: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 387 MEXICO: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 388 MEXICO: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 389 MEXICO: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 390 MEXICO: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 391 REST OF LATIN AMERICA: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 392 REST OF LATIN AMERICA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 393 REST OF LATIN AMERICA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 394 REST OF LATIN AMERICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 395 REST OF LATIN AMERICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)
  • TABLE 396 REST OF LATIN AMERICA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 397 REST OF LATIN AMERICA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 398 REST OF LATIN AMERICA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 399 REST OF LATIN AMERICA: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 400 REST OF LATIN AMERICA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 401 REST OF LATIN AMERICA: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 402 REST OF LATIN AMERICA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 403 REST OF LATIN AMERICA: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 404 REST OF LATIN AMERICA: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 405 MIDDLE EAST & AFRICA: BIOSURGERY MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 406 MIDDLE EAST & AFRICA: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 407 MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 408 MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 409 MIDDLE EAST & AFRICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 410 MIDDLE EAST & AFRICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)
  • TABLE 411 MIDDLE EAST & AFRICA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 412 MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 413 MIDDLE EAST & AFRICA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 414 MIDDLE EAST & AFRICA: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 415 MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 416 MIDDLE EAST & AFRICA: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 417 MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 418 MIDDLE EAST & AFRICA: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 419 MIDDLE EAST & AFRICA: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 420 GCC COUNTRIES: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 421 GCC COUNTRIES: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 422 GCC COUNTRIES: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 423 GCC COUNTRIES: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 424 GCC COUNTRIES: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)
  • TABLE 425 GCC COUNTRIES: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 426 GCC COUNTRIES: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 427 GCC COUNTRIES: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 428 GCC COUNTRIES: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 429 GCC COUNTRIES: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 430 GCC COUNTRIES: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 431 GCC COUNTRIES: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 432 GCC COUNTRIES: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 433 GCC COUNTRIES: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 434 REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 435 REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 436 REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 437 REST OF MIDDLE EAST & AFRICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 438 REST OF MIDDLE EAST & AFRICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)
  • TABLE 439 REST OF MIDDLE EAST & AFRICA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 440 REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 441 REST OF MIDDLE EAST & AFRICA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 442 REST OF MIDDLE EAST & AFRICA: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 443 REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 444 REST OF MIDDLE EAST & AFRICA: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 445 REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 446 REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 447 REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 448 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN BIOSURGERY MARKET
  • TABLE 449 BIOSURGERY MARKET: DEGREE OF COMPETITION
  • TABLE 450 BIOSURGERY MARKET: REGION FOOTPRINT
  • TABLE 451 BIOSURGERY MARKET: PRODUCT FOOTPRINT
  • TABLE 452 BIOSURGERY MARKET: APPLICATION FOOTPRINT
  • TABLE 453 BIOSURGERY MARKET: END-USER FOOTPRINT
  • TABLE 454 BIOSURGERY MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
  • TABLE 455 BIOSURGERY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY PRODUCT AND REGION
  • TABLE 456 BIOSURGERY MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025
  • TABLE 457 BIOSURGERY MARKET: DEALS, JANUARY 2022–JUNE 2025
  • TABLE 458 BAXTER: COMPANY OVERVIEW
  • TABLE 459 BAXTER: PRODUCTS OFFERED
  • TABLE 460 B BRAUN SE: COMPANY OVERVIEW
  • TABLE 461 B BRAUN SE: PRODUCTS OFFERED
  • TABLE 462 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW
  • TABLE 463 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED
  • TABLE 464 JOHNSON & JOHNSON: COMPANY OVERVIEW
  • TABLE 465 JOHNSON & JOHNSON: PRODUCTS OFFERED
  • TABLE 466 MEDTRONIC: COMPANY OVERVIEW
  • TABLE 467 MEDTRONIC: PRODUCTS OFFERED
  • TABLE 468 INTEGRA LIFESCIENCES CORPORATION: COMPANY OVERVIEW
  • TABLE 469 INTEGRA LIFESCIENCES CORPORATION: PRODUCTS OFFERED
  • TABLE 470 COMMONWEALTH SERUM LABORATORIES LIMITED (CSL): COMPANY OVERVIEW
  • TABLE 471 COMMONWEALTH SERUM LABORATORIES LIMITED (CSL): PRODUCTS OFFERED
  • TABLE 472 HEMOSTASIS, LLC: COMPANY OVERVIEW
  • TABLE 473 HEMOSTASIS, LLC: PRODUCTS OFFERED
  • TABLE 474 PFIZER INC.: COMPANY OVERVIEW
  • TABLE 475 PFIZER INC.: PRODUCTS OFFERED
  • TABLE 476 STRYKER: COMPANY OVERVIEW
  • TABLE 477 STRYKER: PRODUCTS OFFERED
  • TABLE 478 ARTIVION, INC.: COMPANY OVERVIEW
  • TABLE 479 ARTIVION, INC.: PRODUCTS OFFERED
  • TABLE 480 ZIMMER BIOMET: COMPANY OVERVIEW
  • TABLE 481 ZIMMER BIOMET: PRODUCTS OFFERED
  • TABLE 482 ZIMMER BIOMET: DEALS, JANUARY 2022–JUNE 2025
  • TABLE 483 KUROS BIOSCIENCES: COMPANY OVERVIEW
  • TABLE 484 KUROS BIOSCIENCES: PRODUCTS OFFERED
  • TABLE 485 KUROS BIOSCIENCES: PRODUCT APPROVALS, JANUARY 2021–JUNE 2025
  • TABLE 486 KUROS BIOSCIENCES: DEALS, JANUARY 2022–JUNE 2025
  • TABLE 487 ORTHOFIX MEDICAL INC.: COMPANY OVERVIEW
  • TABLE 488 ORTHOFIX MEDICAL INC.: PRODUCTS OFFERED
  • TABLE 489 ORTHOFIX MEDICAL INC.: PRODUCT LAUNCHES, JANUARY 2021–JUNE 2025
  • TABLE 490 ORTHOFIX MEDICAL INC.: DEALS, JANUARY 2022–JUNE 2025
  • TABLE 491 SMITH & NEPHEW: COMPANY OVERVIEW
  • TABLE 492 SMITH & NEPHEW: PRODUCTS OFFERED
  • TABLE 493 TISSUE REGENIX: COMPANY OVERVIEW
  • TABLE 494 BETATECH MEDICAL: COMPANY OVERVIEW
  • TABLE 495 MERIL LIFE SCIENCES PVT. LTD.: COMPANY OVERVIEW
  • TABLE 496 GLOBUS MEDICAL: COMPANY OVERVIEW
  • TABLE 497 SAMYANG HOLDINGS CORPORATION: COMPANY OVERVIEW
  • TABLE 498 AROA BIOSURGERY LIMITED: COMPANY OVERVIEW
  • TABLE 499 MEYER-HAAKE GMBH: COMPANY OVERVIEW
  • TABLE 500 ADVANCED MEDICAL SOLUTIONS GROUP PLC: COMPANY OVERVIEW
  • TABLE 501 BIOCER ENTWICKLUNGS-GMBH: COMPANY OVERVIEW
  • TABLE 502 WILTROM: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 BIOSURGERY MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 BIOSURGERY MARKET: YEARS CONSIDERED
  • FIGURE 3 BIOSURGERY MARKET: RESEARCH DESIGN
  • FIGURE 4 BIOSURGERY MARKET: KEY DATA FROM SECONDARY SOURCES
  • FIGURE 5 BIOSURGERY MARKET: KEY PRIMARY SOURCES (DEMAND AND SUPPLY SIDES)
  • FIGURE 6 BIOSURGERY MARKET: KEY DATA FROM PRIMARY SOURCES
  • FIGURE 7 BIOSURGERY MARKET: KEY INDUSTRY INSIGHTS
  • FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 9 BIOSURGERY MARKET SIZE ESTIMATION (REVENUE SHARE ANALYSIS)
  • FIGURE 10 BIOSURGERY MARKET: TOP-DOWN APPROACH
  • FIGURE 11 IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2025–2030)
  • FIGURE 12 BIOSURGERY MARKET: CAGR PROJECTIONS
  • FIGURE 13 BIOSURGERY MARKET: DATA TRIANGULATION METHODOLOGY
  • FIGURE 14 BIOSURGERY MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 BIOSURGERY MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 16 BIOSURGERY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 17 BIOSURGERY MARKET: REGIONAL SNAPSHOT
  • FIGURE 18 RISING SURGICAL VOLUMES AND INCREASING FOCUS ON MEDICAL TOURISM TO DRIVE MARKET
  • FIGURE 19 US AND HOSPITALS SEGMENT COMMANDED LARGEST NORTH AMERICAN MARKET SHARE IN 2024
  • FIGURE 20 INDIA TO WITNESS HIGHEST CAGR DURING STUDY PERIOD
  • FIGURE 21 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE FROM 2025 TO 2030
  • FIGURE 22 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
  • FIGURE 23 BIOSURGERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 24 BIOSURGERY MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 25 BIOSURGERY MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 26 BIOSURGERY MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 27 BIOSURGERY MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 28 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF TOP THREE BIOSURGERY PRODUCTS
  • FIGURE 29 KEY BUYING CRITERIA FOR BIOSURGERY PRODUCTS
  • FIGURE 30 CANADA: CLASS III MEDICAL DEVICE APPROVAL PROCESS
  • FIGURE 31 TOP 10 COMPANIES WITH HIGHEST NUMBER OF PATENTS APPLIED/PUBLISHED (JANUARY 2014–JUNE 2025)
  • FIGURE 32 TOP APPLICANT COUNTRIES/REGIONS FOR BIOSURGERY PATENTS (JANUARY 2014− MAY 2025)
  • FIGURE 33 ADJACENT MARKET ANALYSIS: ADHESION BARRIERS MARKET (MARKET OVERVIEW)
  • FIGURE 34 BIOSURGERY MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
  • FIGURE 35 BIOSURGERY MARKET: FUNDING AND NUMBER OF DEALS, 2019–2023 (USD MILLION)
  • FIGURE 36 KEY FEATURES OF AI/GEN AI IN BIOSURGERY MARKET
  • FIGURE 37 BIOSURGERY MARKET: GEOGRAPHIC SNAPSHOT
  • FIGURE 38 NORTH AMERICA: BIOSURGERY MARKET SNAPSHOT
  • FIGURE 39 ASIA PACIFIC: BIOSURGERY MARKET SNAPSHOT
  • FIGURE 40 REVENUE ANALYSIS OF KEY PLAYERS IN BIOSURGERY MARKET (2020–2024)
  • FIGURE 41 MARKET SHARE ANALYSIS OF KEY PLAYERS IN BIOSURGERY MARKET (2024)
  • FIGURE 42 BIOSURGERY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 43 BIOSURGERY MARKET: COMPANY FOOTPRINT
  • FIGURE 44 BIOSURGERY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 45 EV/EBITDA OF KEY VENDORS
  • FIGURE 46 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 47 BIOSURGERY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 48 BAXTER: COMPANY SNAPSHOT
  • FIGURE 49 B BRAUN SE: COMPANY SNAPSHOT
  • FIGURE 50 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT
  • FIGURE 51 JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • FIGURE 52 MEDTRONIC: COMPANY SNAPSHOT
  • FIGURE 53 INTEGRA LIFESCIENCES CORPORATION: COMPANY SNAPSHOT
  • FIGURE 54 COMMONWEALTH SERUM LABORATORIES LIMITED (CSL): COMPANY SNAPSHOT
  • FIGURE 55 PFIZER INC.: COMPANY SNAPSHOT
  • FIGURE 56 STRYKER: COMPANY SNAPSHOT
  • FIGURE 57 ARTIVION, INC.: COMPANY SNAPSHOT
  • FIGURE 58 ZIMMER BIOMET: COMPANY SNAPSHOT
  • FIGURE 59 KUROS BIOSCIENCES: COMPANY SNAPSHOT
  • FIGURE 60 ORTHOFIX MEDICAL INC.: COMPANY SNAPSHOT
  • FIGURE 61 SMITH & NEPHEW: COMPANY SNAPSHOT

 

The study involved major activities in estimating the current market size for the biosurgery market. Exhaustive secondary research was done to collect information on the biosurgery industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the Biosurgery market.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, investor presentations, SEC filings of companies and publications from government sources [such as National Institutes of Health (NIH), US FDA, US Census Bureau, World Health Organization (WHO), International Trade Administration (ITA), Global Burden of Disease Study, and Centers for Medicare and Medicaid Services (CMS) were referred to identify and collect information for the global biosurgery market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various supply and demand sources were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the biosurgery market. The primary sources from the demand side include ambulatory surgical centers, hospitals, Clinics, and other end users. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on key industry trends & key market dynamics.

A breakdown of the primary respondents is provided below:

Biosurgery Market

*C-level primaries include CEOs, CFOs, COOs, and VPs.

*Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

Note: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = < USD 1.00 billion.

Source: MarketsandMarkets Analysis

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

For the global market value, annual revenues were calculated based on the revenue mapping of major product manufacturers and OEMs active in the global biosurgery market. All the major product manufacturers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/sub-segments was done for the major players. Also, the global biosurgery market was split into various segments and sub-segments based on:

  • List of major players operating in the products market at the regional and/or country level
  • Product mapping of various biosurgery manufacturers at the regional and/or country level
  • Mapping of annual revenue generated by listed major players from biosurgery (or the nearest reported business unit/product category)
  • Extrapolation of the revenue mapping of the listed major players to derive the global market value of the respective segments/subsegments
  • Summation of the market value of all segments/subsegments to arrive at the global biosurgery market

The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.

Market Size Estimation (Bottom-up Approach and Top-down Approach)

Biosurgery Market

Data Triangulation

After arriving at the global biosurgery market's overall size through the methodology mentioned above, this market was split into several segments and subsegments. Where applicable, the data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact market value data for the key segments and subsegments. The extrapolated market data was triangulated by studying various macro indicators and regional trends from both demand- and supply-side participants.

Market Definition

Biosurgery products are essential in surgical procedures, aiding in the repair of damaged tissues and bones. Surgeons utilize these products to stabilize skin, internal organs, and blood vessels, ensuring hemostasis and tissue integrity after injury or surgery. Key types include surgical sealants, hemostatic agents, adhesion barriers, soft-tissue attachments, bone-graft substitutes, and staple-line reinforcement agents, all designed to enhance healing and prevent complications.

Stakeholders

  • Transfection products manufacturing companies
  • Pharmaceutical & Biopharmaceutical Companies
  • Chemical Companies
  • Biopharmaceutical Companies
  • Contract Research Organizations (CROs)
  • Contract Development and Manufacturing Organizations (CDMOs)
  • Research Institutes and Universities 
  • Venture Capitalists & Investors
  • Government Associations

Report Objectives

  • To define, describe, segment, and forecast the transfection technologies market by product type, method, application, end user, and region
  • To provide detailed information about the major factors (such as drivers, restraints, opportunities, and challenges) influencing the market growth
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the transfection technologies market in five main regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, along with their respective key countries
  • To profile the key players in the transfection technologies market and comprehensively analyze their core competencies2 and market shares
  • To track and analyze competitive developments, such as product launches, acquisitions, expansions, collaborations, agreements, and partnerships of the leading players in the transfection technologies market
  • To benchmark players within the transfection technologies market using the ‘Competitive Leadership Mapping’ framework, which analyzes market players based on various parameters, including product portfolio, geographic reach, and market share/rank

Previous Versions of this Report

Biosurgery Market by Product Type (Sealants, Hemostats, Adhesion Barrier, Soft Tissue Attachments, Biological Meshes, DBM, Bone Graft Substitutes), Application (Orthopedic, Cardiovascular), End User (Hospitals, Clinics) - Global Forecast to 2026

Report Code MD 3554
Published in Jun, 2021, By MarketsandMarkets™

Biosurgery Market by Product (Fibrin & Collagen Sealant, Hemostats, Adhesion Barriers, Biological Meshs, Soft Tissue Attachments, Stapler, Bone Graft Substitutes) Application (Orthopedic, Gynecology, Cardiovascular, Reconstructive) - Forecast to 2023

Report Code MD 3554
Published in Jul, 2018, By MarketsandMarkets™

Biosurgery Market by Product (Fibrin & Collagen Sealant, Hemostats, Adhesion Barriers, Biological Meshs, Soft Tissue Attachments, Stapler, Bone Graft Substitues) Application (Orthopedic, Gynecology, Cardiovascular, Reconstructive) - Forecast to 2021

Report Code MD 3554
Published in Nov, 2016, By MarketsandMarkets™

Biosurgery Market by Type (Surgical Sealants, Hemostatic Agents, Soft Tissue Attachments, Adhesion Barriers, Bone Graft Substitutes), Application (Neurological, Cardiovascular, General, Orthopedic, Reconstructive) - Global Forecast to 2020

Report Code MD 3554
Published in Jun, 2015, By MarketsandMarkets™
"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.


By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Biosurgery Market

Edward

Oct, 2022

What are the latest technological trends in biosurgery products?.

Tyler

Oct, 2022

What are the latest innovations in Biosurgery Market?.

Matthew

Oct, 2022

Which region to focus more for business expansion in Biosurgery Market?.

DMCA.com Protection Status